ÂÜŔňÂŇÂ×

Dr. Gollaher is currently Head of Policy and Government Affairsat Vir Biotechnology, Inc., a role he has held since May 2019. Previously, Dr. Gollaher served as the Vice President of Global Government Affairs and Policy for Gilead Sciences from early 2014 to mid-2018, a period during

which the company launched a breakthrough cure for hepatitis C (HCV) and tripled revenues from $10 billion to $30 billion. In addition to the introduction of three novel drugs for HCV, building on Gilead’s strength in virology, he was involved in the launch of a new generation of medicines for HIV/AIDS. Before joining Gilead, Dr. Gollaher was Co-Founder and Chief Executive Officerof the California Healthcare Institute (CHI). From 1993 to 2013,he built CHI into the nation’s premier state-based life sciences policy research and advocacy association, with offices in La Jolla, Washington D.C. and Sacramento, representing some 370 biopharma, medical device and diagnostics companies, along with leading academic institutions, venture capital and professional services firms. In 2018, Dr. Gollaherwas appointed Quintiles Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. In addition, he serves on the Board of Overseers for Scripps Research. Earlier in his career, Dr. Gollaher was Vice President at Scripps Clinic and Research Foundation, responsible for managed care, strategy and corporate affairs. He earned his B.A. from UCSB and his master’s and Ph.D. degrees, concentrating in the History of Science and Medicine, from Harvard University.